Wang et al. elucidated that Vascular Endothelial Growth Factor Receptor-1 (VEGFR-1) CAR T-cells attenuate resistance to traditional treatments directed at angiogenesis, concurrently enhancing the tumor-killing capacity of CAR T-cells [124]. Here, FLT1 is linked to neoplasm.